Participated · Series B · Nov 2023

Meju develops HiCardi, a remote patient real-time monitoring platform used for continuous vital-sign tracking. The company has commercial partnerships including a domestic distribution agreement with 동아ST and a memorandum with HL만도 to develop Digital Healthcare Automotive solutions. Meju is expanding HiCardi beyond healthcare into industrial safety monitoring for construction and factory workers and is in final negotiations with a Korean public enterprise for product supply. Financially, Meju reported approximately ₩1.4bn in revenue in 2022, is targeting ₩4.0bn in 2023, and aims for ₩10.0bn in revenue by 2025 to reach breakeven. Its investors have cited the company’s technology, commercialization progress, and growth potential when committing capital.

Participated · Series D · Nov 2021

Antiva Biosciences is a clinical-stage biopharmaceutical company focused on novel topical therapeutics to treat diseases caused by human papilloma virus (HPV) infection. Its lead candidate, ABI-2280, is being developed as a topical vaginal tablet for high-grade cervical intraepithelial neoplasia (HSIL, CIN 2,3) and for women with high-risk HPV infection. ABI-2280 is reported to have potent antiviral activity across all HPV serotypes, working by blocking HPV replication and inducing apoptosis in infected lesions while sparing normal cells. Antiva plans to advance ABI-2280 into key efficacy studies after completing ongoing Phase 1 trials, including a Phase 2 trial in CIN 2,3 and an exploratory study for high-risk HPV subtypes that can lead to cancer. The company has formulated a self-administered vaginal tablet to facilitate diagnosis-time treatment and worldwide distribution. The recently closed financing will underwrite these clinical programs and support development into late 2025. Antiva Biosciences is a clinical-stage biopharmaceutical company focused on novel topical therapeutics for diseases caused by HPV infection. Its lead candidate, ABI-2280, is a topical prodrug of an acyclic nucleoside phosphonate that directly blocks HPV replication and induces apoptosis in infected lesions while sparing normal cells. The company formulated ABI-2280 for rapid uptake into epithelial cells to avoid potential systemic toxicity. Proceeds from a $31 million Series D will support advancement of ABI-2280 into Phase 1 and 2a clinical trials, with a Phase 1 initiation planned for Q4 2021 and data expected in the first half of 2022. Antiva is establishing a global health committee to accelerate development and commercialization in lower- and middle-income countries and intends to expand development to other HPV-attributed pre-cancers such as vulvar and anal neoplasias. The company is based in South San Francisco and was founded in 2012. Antiva Biosciences is a biopharmaceutical company developing novel topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection. Its lead compound, ABI-1968, is being assessed in two Phase 1b clinical studies: intravaginal delivery for women with high-grade cervical intraepithelial neoplasia (CIN 2,3) and topical treatment for high-grade anal intraepithelial neoplasia (AIN 2,3). The company notes there are currently no FDA-approved drugs for either indication. Antiva intends to use the funds from its recent financing to support additional clinical studies in both indications over the next year. Founded in 2012 and led by president and CEO Gail Maderis, Antiva was cofounded by Dr. Karl Hostetler of UC San Diego and is based in South San Francisco, CA. The company has raised a $15M Series C-1 to advance these clinical programs. Antiva Biosciences develops novel topical therapeutics to treat diseases caused by human papilloma virus (HPV) infection, notably precancerous cervical lesions. Its lead compound is ABI-1968, a topical therapy intended for intravaginal administration. The company recently initiated a Phase 1 study to assess tolerability and safety of ABI-1968 in healthy women and plans a Phase 1b study in patients with high-grade cervical intraepithelial neoplasia (CIN 2,3) later this year. Antiva intends to use the proceeds from its financing to advance ABI-1968 into clinical studies. The company was founded in 2012 and is based in South San Francisco, CA, and is led by president and CEO Gail Maderis. Antiva positions its product approach as a non-surgical, topical option for HPV-related precancerous conditions. Antiva Biosciences (formerly Hera Therapeutics) is a Menlo Park, CA–based biopharmaceutical company using a medicinal chemistry platform to develop antiviral therapies. Its lead program is ABI-1968, a topical antiviral for treatment of high‑risk human papillomavirus (HPV) infections, the primary cause of cervical cancer. The company has additional molecules targeting HIV, herpes virus, cytomegalovirus and other viral indications. Antiva intends to advance ABI-1968 into Phase 1 clinical trials using proceeds from its recent financing. Leadership changes announced alongside the financing include Gail Maderis as president and CEO and Steven P. James as executive chairman of the board. The company is positioning its platform to generate multiple antiviral candidates beyond its HPV program.